ReviewFrontiers in cellular and infection microbiology2026
Beyond viral suppression: combining PEG-interferon with novel immunotherapies for functional cure of chronic hepatitis B.
Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis B (CHB) affects approximately 250 million people worldwide. The major barrier to cure lies in the persistent presence of covalently closed circular DNA (cccDNA) and integrated HBV DNA within hepatocytes, which continuously drive hepatitis B surface antigen (HBsAg) expression and maintain immune tolerance, thereby leading to functional exhaustion of antiviral effector cells. Although nucleos(t)ide analogues (NAs) effectively suppress viral replication, they have limited impact on cccDNA activity and antigen production. In contrast, pegylated interferon-α (PEG-IFN-α) enhances antigen presentation, activates innate immunity, and partially restores HBV-specific T cell function, thereby contributing to the disruption of immune tolerance to some extent. However, its therapeutic efficacy remains influenced by host immune status and antigen burden. With the development of antigen-reduction strategies (such as siRNA/antisense oligonucleotides [ASO] and HBsAg-targeting monoclonal antibodies), therapeutic vaccines, and immune-modulatory approaches, PEG-IFN-α is increasingly being incorporated into combination therapies. This review summarizes its immunological basis and clinical advances, and further discusses biomarker-driven patient stratification strategies, with the aim of improving functional cure rates in CHB.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.